[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555523":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":37,"responsibleParty":56,"collaborators":31,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":31,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":31,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":40,"whyStopped":31,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Universitaire Ziekenhuizen KU Leuven","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"EUS-PPG before and after NSBB","EXPERIMENTAL","Patients will undergo EUS-PPG and HVPG before and after NSBB treatment and will thus serve as their own control.",[13],"Procedure: endoscopic ultrasound-guided portal pressure measurement",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"PROCEDURE","endoscopic ultrasound-guided portal pressure measurement","The portal pressure gradient will be determined by endoscopic ultrasound-guided pressure measurement in the hepatic vein and the portal vein. The gradient will be calculated by substracting the hepatic vein pressure from the portal vein pressure.",[9],[21],"EUS-PPG",[23],{"name":24,"affiliation":5,"role":25},"Schalk van der Merwe, MD, PhD","PRINCIPAL_INVESTIGATOR",[27,33],{"name":28,"role":29,"phone":30,"phoneExt":31,"email":32},"Emma Vanderschueren, MD","CONTACT","0032 16 345918",null,"emma.vanderschueren@uzleuven.be",{"name":34,"role":29,"phone":35,"phoneExt":31,"email":36},"Petra Windmolders","003216 347581","petra.windmolders@uzleuven.be",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"University Hospital Leuven","RECRUITING","Leuven","Vlaams-Brabant","3000","Belgium","BE",{"type":47,"coordinates":48},"Point",[49,50],4.70093,50.87959,{"lat":50,"lon":49},[53],{"name":28,"role":29,"phone":54,"phoneExt":55,"email":32},"000-000-0000","003216349518",{"type":57,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100555523","eus-guided-response-assessment-to-nsbb-100555523",false,"NCT06513195","EUS-guided Response Assessment to NSBB","Endoscopic Ultrasound Guided Response Assessment to Non-selective Beta-blockers in the Treatment of Clinically Significant Portal Hypertension","Inclusion Criteria:\n\n* Patients with a clinical and\u002For pathological diagnosis of compensated cirrhosis.\n* Patients with suspicion of CSPH and thus indication for NSBB treatment.\n* Patients not yet on NSBB therapy.\n* Patients willing and able to undergo repeated HVPG and EUS-guided pressure measurements as per protocol.\n\nExclusion Criteria:\n\nGeneral criteria\n\n* Patient is \\\u003C18 or \\>80 years of age\n* Patient is pregnant, breast-feeding or planning to become pregnant during the course of the study\n* Patient is unwilling or unable to sign the informed consent\n* Patients in whom general anesthesia or endoscopic procedures are contraindicated Medical criteria\n* Patients with cirrhosis and HCC Portopulmonary hypertension Portal or splanchnic venous thrombosis Prior TIPS Prior liver transplantation\n* Non-cirrhotic portal hypertension or pre-sinusoidal liver disease\n* Cholestatic liver disease with total bilirubin \\>3 mg\u002Fdl\n* Previous total or partial splenectomy\n* Known infection that is not controlled by medical intervention\n* Patients with contraindications for non-selective beta-blocker therapy, including but not limited to the following baseline vital signs:\n\nSystolic BP \\\u003C100 mmHg HR \\\u003C50 bpm\n\n* Patients with reduced life expectancy described by an ASA score of 4 or 5\n* INR \\>1.7 or platelet count \\\u003C50.000 per mm3\n* eGFR \\\u003C50 ml\u002Fmin\u002F1.73m2 (CKD-EPI formula) Anatomical criteria\n* Anatomical abnormalities that prevent access via EUS-guided puncture to the hepatic vein or intrahepatic portion of the portal vein, including anatomy that predisposes to difficult to reach puncture sites or an inadequate needle angle.\n* Visualization of ascites interposing the puncture tract on EUS\n* Diagnosis of portal vein thrombosis during EUS\n* Evidence of active gastrointestinal bleeding during EUS","ALL","18 Years","80 Years",{"count":69,"type":70},24,"ESTIMATED","INTERVENTIONAL",[73],"NA","The goal of this clinical trial is to learn if endoscopic ultrasound (EUS)-guided portal pressure measurement can determine the treatment response to non-selective beta-blockers (NSBB) in patients with cirrhosis and clinically significant portal hypertension (CSPH). Participants will undergo EUS-guided portal pressure measurement before start of Carvedilol en after three months of treatment. EUS-guided measurements will be paired with transjugular hepatic venous pressure gradient (HVPG) measurement as well as non-invasive tests for assessment of portal hypertension.",[76],"Portal Hypertension Related to Cirrhosis",[78,21,79,80,81],"portal hypertension","HVPG","cirrhosis","non-selective beta blockers","2026-06-02",{"date":84,"type":85},"2026-06-03","ACTUAL",{"date":87,"type":85},"2024-07-17",{"date":89,"type":70},"2026-12",{"name":5,"class":6},1]